PT - JOURNAL ARTICLE AU - Sharma, Kavi AU - Berry, Lisa AU - Vryonis, Evangelos AU - Ali, Asad AU - Lara, Beatriz AU - Noufaily, Angela AU - Parsons, Nick AU - Bradley, Christopher James AU - Haley, Becky AU - Maria, Tabuso AU - Arasaradnam, Ramesh TI - Prospective, Randomized, Parallel-Group, Open-Label Study to Evaluate the Efficacy and Safety of IMU-838, in Combination with Oseltamivir, in Adults with Coronavirus-19 – The IONIC Trial Protocol AID - 10.1101/2021.07.13.21258757 DP - 2021 Jan 01 TA - medRxiv PG - 2021.07.13.21258757 4099 - http://medrxiv.org/content/early/2021/07/15/2021.07.13.21258757.short 4100 - http://medrxiv.org/content/early/2021/07/15/2021.07.13.21258757.full AB - Background Globally there is a scarcity of effective treatments for SARS-CoV-2 infections (causing COVID 19). Repurposing existing medications may offer the best hope for treating COVID 19 patients to curb the pandemic. IMU-838 is a dihydroorotate dehydrogenase (DHODH) inhibitor, which is an effective mechanism for antiviral effects against respiratory viruses. When used synergistically with Oseltamivir, therapeutic effects have been observed against influenza and SARS-CoV-2 in rodents.(13) The IONIC trial is a randomized control trial that will investigate whether time to clinical improvement in COVID 19 patients is improved following a 14 day course of IMU-838 + Oseltamivir versus Oseltamivir alone.Methods IONIC trial is an open label study in which participants will be randomised 1:1 in two parallel arms; the intervention arm (IMU-838 + Oseltamivir) and control arm (Oseltamivir only). The primary outcome is time-to-clinical improvement; defined as the time from randomisation to: a 2-point improvement on WHO ordinal scale; discharge from hospital, or death (whichever occurs first). The study is sponsored by UHCW NHS Trust and funded by LifeArc.Discussion The IONIC Protocol describes an overarching trial design to provide reliable evidence on the efficacy of IMU-838 (vidofludimus calcium) when delivered in combination with an antiviral therapy (Oseltamivir) [IONIC Intervention] for confirmed or suspected COVID-19 infection in adult patients receiving usual standard of care.Trial Registration The trial was registered with EudraCT (2020-001805-21) on 09.04.2020 and ISRCTN on 23.09.2020 (ISRCTN53038326) and Clinicaltrials.gov on 17.08.2020 (NCT04516915)Strengths and Limitations This study is the first to recruit participants in the trial exploring the effectiveness of IMU-838 in COVID-19. In addition, we believe it is the only trial exploring the effectiveness of IMU-838 in combination with Oseltamivir (Tamiflu) in patients with moderate to severe COVID-19. However, to make the trial design flexible due to the on-going pandemic the trial is un-blinded.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT04516915 ISRCTN53038326Funding StatementThe main phase of the study has received funding from LifeArc organisation. Immunic Therapeutics the manufacturer of IMU-838 has provided the funding for the trial drug used for this trial. The funding source had no role in the design of this study and will not have any role during its execution, analysis, interpretation of the data, or decision to submit resultsAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study has been independently reviewed and approved by Wales Research Ethics Committee (Ref No: 20/WA/0146); Health Research Authority (HRA) Approval was granted on 15/05/2020. In addition, required regulatory approvals were received from Medicines and Healthcare products Regulatory Agency (MHRA).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData from this study will be made available to researchers who provide a methodologically sound proposal in writing to the Sponsor, following the publication of the main study paper. Anonymised, individual participant data, data dictionary, study protocol and statistical analysis plan will be accessible upon application.